Actively Recruiting
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Led by One-carbon Therapeutics AB · Updated on 2026-01-28
43
Participants Needed
4
Research Sites
66 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.
CONDITIONS
Official Title
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must have given written informed consent
- Histopathologically confirmed advanced cancer (colorectal cancer, head and neck squamous cell cancer, non-small cell lung cancer and gastric cancer including gastroesophageal junction cancer)
- Prior treatment with at least one line of cytotoxic systemic therapy for metastatic or unresectable cancer
- Adult patients (18 years of age or older)
- Must be willing to comply with study procedures
You will not qualify if you...
- History or presence of any clinically significant disorders as judged by the Investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Institut Gustave Roussy
Villejuif, France
Actively Recruiting
2
Vall D Hebron Institute Of Oncology
Barcelona, Spain
Actively Recruiting
3
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Actively Recruiting
4
Newcastle University
Newcastle upon Tyne, United Kingdom
Actively Recruiting
Research Team
V
Victoria Moody
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here